Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR
暂无分享,去创建一个
D. Sheppard | Z. Cai | H. D. de Jonge | Jia Liu | Yiting Wang | M. Bijvelds | A. Bot | Samuel J. Bose
[1] D. Sheppard,et al. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl- channel by ivacaftor is temperature independent. , 2018, American journal of physiology. Lung cellular and molecular physiology.
[2] R. Young,et al. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del , 2018, Molecular Pharmacology.
[3] T. Hwang,et al. Structural mechanisms of CFTR function and dysfunction , 2018, The Journal of general physiology.
[4] S. Rousseau,et al. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells. , 2018, American journal of physiology. Lung cellular and molecular physiology.
[5] A. Ashare,et al. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa. , 2018, American journal of physiology. Lung cellular and molecular physiology.
[6] S. Muallem,et al. Original ResearchFull Report: Basic and Translational—PancreasRestoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice , 2017 .
[7] M. Claustres,et al. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. , 2017, The international journal of biochemistry & cell biology.
[8] David Y. Thomas,et al. Corrector combination therapies for F508del-CFTR. , 2017, Current opinion in pharmacology.
[9] I. Braakman,et al. Correcting CFTR folding defects by small‐molecule correctors to cure cystic fibrosis , 2017, Current opinion in pharmacology.
[10] Y. Sohma,et al. CFTR potentiators: from bench to bedside , 2017, Current opinion in pharmacology.
[11] N. McCarty,et al. Bacterial Sphingomyelinase is a State-Dependent Inhibitor of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) , 2017, Scientific Reports.
[12] R. Ford,et al. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation* , 2017, The Journal of Biological Chemistry.
[13] M. Gray,et al. Role of CFTR in epithelial physiology , 2016, Cellular and Molecular Life Sciences.
[14] H. Senderowitz,et al. Potentiators exert distinct effects on human, murine, and Xenopus CFTR. , 2016, American journal of physiology. Lung cellular and molecular physiology.
[15] D. Meyerholz,et al. Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility. , 2016, American journal of respiratory and critical care medicine.
[16] David K. Meyerholz,et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice , 2016, Science.
[17] N. McCarty,et al. Murine and human CFTR exhibit different sensitivities to CFTR potentiators. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[18] D. Sheppard,et al. Exploiting species differences to understand the CFTR Cl- channel. , 2015, Biochemical Society transactions.
[19] Asmahan Abu-Arish,et al. Cholesterol modulates CFTR confinement in the plasma membrane of primary epithelial cells. , 2015, Biophysical journal.
[20] I. Callebaut,et al. Impact of the F508del mutation on ovine CFTR, a Cl− channel with enhanced conductance and ATP‐dependent gating , 2015, The Journal of physiology.
[21] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[22] A. Toye,et al. CFTR potentiators partially restore channel function to A561E‐CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del‐CFTR , 2014, British Journal of Pharmacology.
[23] O. Moran,et al. Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers , 2014, European Biophysics Journal.
[24] N. Pedemonte,et al. Structure and function of TMEM16 proteins (anoctamins). , 2014, Physiological reviews.
[25] Marisa Sousa,et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.
[26] G. Lukács,et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.
[27] T. Hwang,et al. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle , 2013, Proceedings of the National Academy of Sciences.
[28] C. Bear,et al. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner* ♦ , 2012, The Journal of Biological Chemistry.
[29] Pradeep Kota,et al. Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.
[30] G. Lukács,et al. Comparative Processing and Function of Human and Ferret Cystic Fibrosis Transmembrane Conductance Regulator* , 2012, The Journal of Biological Chemistry.
[31] K. Du,et al. Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.
[32] Philip J. Thomas,et al. Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.
[33] M. Welsh,et al. Human–mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect , 2011, Proceedings of the National Academy of Sciences.
[34] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[35] K. Kirk,et al. Thermally Unstable Gating of the Most Common Cystic Fibrosis Mutant Channel (ΔF508) , 2011, The Journal of Biological Chemistry.
[36] T. Hwang,et al. The most common cystic fibrosis‐associated mutation destabilizes the dimeric state of the nucleotide‐binding domains of CFTR , 2011, The Journal of physiology.
[37] L. Touqui,et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[38] Tzyh-Chang Hwang,et al. On the mechanism of CFTR inhibition by a thiazolidinone derivative , 2010, The Journal of general physiology.
[39] Philip J. Thomas,et al. The Primary Folding Defect and Rescue of ΔF508 CFTR Emerge during Translation of the Mutant Domain , 2010, PloS one.
[40] J. Clancy,et al. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. , 2010, Pulmonary pharmacology & therapeutics.
[41] Bart Kus,et al. Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine , 2010, Molecular Pharmacology.
[42] N. Pedemonte,et al. Influence of cell background on pharmacological rescue of mutant CFTR. , 2010, American journal of physiology. Cell physiology.
[43] D. Sheppard,et al. Direct Sensing of Intracellular pH by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl− Channel*♦ , 2009, The Journal of Biological Chemistry.
[44] P. Negulescu,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[45] Gui Jun Yu,et al. 4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing. , 2008, Bioorganic & medicinal chemistry letters.
[46] M. Amaral,et al. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator , 2008, British journal of pharmacology.
[47] Donglei Zhang,et al. Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect , 2008, Molecular Pharmacology.
[48] D. Porteous,et al. Chimeric constructs endow the human CFTR Cl− channel with the gating behavior of murine CFTR , 2007, Proceedings of the National Academy of Sciences.
[49] M. Welsh,et al. Processing and function of CFTR-ΔF508 are species-dependent , 2007, Proceedings of the National Academy of Sciences.
[50] A. Houtsmuller,et al. Cholesterol Depletion and Genistein as Tools to Promote F508delCFTR Retention at the Plasma Membrane , 2007, Cellular Physiology and Biochemistry.
[51] Zhe Lu,et al. Inhibition of CFTR Cl− channel function caused by enzymatic hydrolysis of sphingomyelin , 2007, Proceedings of the National Academy of Sciences.
[52] S. Al’Aref,et al. 2,3-Butanedione Monoxime Affects Cystic Fibrosis Transmembrane Conductance Regulator Channel Function through Phosphorylation-Dependent and Phosphorylation-Independent Mechanisms: The Role of Bilayer Material Properties , 2006, Molecular Pharmacology.
[53] T. Kirchhausen,et al. Dynasore, a cell-permeable inhibitor of dynamin. , 2006, Developmental cell.
[54] James Rader,et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[55] A. Taddei,et al. Differential Sensitivity of the Cystic Fibrosis (CF)-associated Mutants G551D and G1349D to Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl– Channel* , 2006, Journal of Biological Chemistry.
[56] Kai Du,et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. , 2005, The Journal of clinical investigation.
[57] J. Clancy,et al. Activating Cystic Fibrosis Transmembrane Conductance Regulator Channels with Pore Blocker Analogs* , 2005, Journal of Biological Chemistry.
[58] Nicoletta Pedemonte,et al. Phenylglycine and Sulfonamide Correctors of Defective ΔF508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating , 2005, Molecular Pharmacology.
[59] Paola Vergani,et al. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains , 2005, Nature.
[60] D. Sheppard,et al. Voltage-dependent Gating of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel , 2003, The Journal of general physiology.
[61] T. Ma,et al. Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating* , 2003, Journal of Biological Chemistry.
[62] Chao Quan,et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.
[63] Nancy F. Hansen,et al. Comparative analyses of multi-species sequences from targeted genomic regions , 2003, Nature.
[64] R. Sammelson,et al. 3-(2-Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. , 2003, Bioorganic & medicinal chemistry letters.
[65] R. Sammelson,et al. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[66] W. Tanner,et al. Specific lipid requirements of membrane proteins--a putative bottleneck in heterologous expression. , 2003, Biochimica et biophysica acta.
[67] A. Nairn,et al. On the Mechanism of MgATP-dependent Gating of CFTR Cl− Channels , 2003, The Journal of general physiology.
[68] L. Gansheroff,et al. Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator ΔF508* , 2002, The Journal of Biological Chemistry.
[69] M. Amaral,et al. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. , 2002, The Biochemical journal.
[70] D. Sheppard,et al. Molecular pharmacology of the CFTR Cl- channel. , 1999, Trends in pharmacological sciences.
[71] J. Riordan,et al. Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. , 1999, Molecular cell.
[72] R. Frizzell,et al. Rescue of Dysfunctional ΔF508-CFTR Chloride Channel Activity by IBMX , 1999, The Journal of Membrane Biology.
[73] B. Wainwright,et al. Regulation of murine cystic fibrosis transmembrane conductance regulator Cl− channels expressed in Chinese hamster ovary cells , 1998, The Journal of physiology.
[74] D. Sheppard,et al. Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Cl− channels expressed in mammalian cells , 1998, The Journal of physiology.
[75] D. Sheppard,et al. Mechanism of Glibenclamide Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channels Expressed in a Murine Cell Line , 1997, The Journal of physiology.
[76] P. French,et al. A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. , 1996, The Journal of clinical investigation.
[77] M. Donowitz,et al. Genistein and tyrphostin 47 stimulate CFTR-mediated Cl- secretion in T84 cell monolayers. , 1995, The American journal of physiology.
[78] K. Thomas,et al. A mouse model for the delta F508 allele of cystic fibrosis. , 1995, The Journal of clinical investigation.
[79] H. Morreau,et al. A mouse model for the cystic fibrosis delta F508 mutation. , 1995, The EMBO journal.
[80] B. Abella,et al. Generation and characterization of a ΔF508 cystic fibrosis mouse model , 1995, Nature Genetics.
[81] R. Frizzell,et al. ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism , 1994, The Journal of general physiology.
[82] V. Gribkoff,et al. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. , 1994, The Journal of biological chemistry.
[83] C. Cotton,et al. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[84] S Grinstein,et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.
[85] Matthew P. Anderson,et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.
[86] P. Parker,et al. Dual role for protein kinase C alpha as a regulator of ion secretion in the HT29cl.19A human colonic cell line. , 1992, The Biochemical journal.
[87] Pascal Barbry,et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.
[88] H. A. Berger,et al. Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. , 1991, The Journal of clinical investigation.
[89] J. Marshall,et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.
[90] L. Tsui,et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.
[91] Kaye Walizer. Defective , 2021, Encyclopedia of the UN Sustainable Development Goals.
[92] C. Goss,et al. Cystic fibrosis , 2015, Nature Reviews Disease Primers.
[93] J. Forrest,et al. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. , 2012, American journal of physiology. Cell physiology.
[94] John R Yates,et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.
[95] M. Welsh,et al. Processing and function of CFTR-DeltaF508 are species-dependent. , 2007, Proceedings of the National Academy of Sciences of the United States of America.
[96] Karl Kuchler,et al. ABC proteins : from bacteria to man , 2003 .
[97] L. Gansheroff,et al. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. , 2002, The Journal of biological chemistry.
[98] R. Frizzell,et al. Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. , 1999, The Journal of membrane biology.
[99] R. Crystal,et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , 1991, Nature.
[100] REVIEW Ion Channels and Transporters in Lung Function and Disease Ion channels of the lung and their role in disease pathogenesis , 2022 .